SMN2 and proximal spinal muscular atrophy: Now that disease-modifying therapies are available to treat primary SMA pathologies (e.g., spinal motoneuron dysfunction and loss), secondary defects arising from chronic SMN deficiency in untargeted peripheral tissues may emerge.